Publications by authors named "George Rivard"
Article Synopsis
- In severe haemophilia A, children typically develop inhibitors to factor VIII soon after starting treatment, which can be classified as low or high titre based on their strength.
- Nearly half of the children studied initially had low-titre inhibitors, with many progressing to high-titre levels over time.
- Key risk factors for this progression include specific genetic mutations, family history of inhibitors, and the use of high-dose immune tolerance induction treatments.
Background: For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development).
Methods: We evaluated 574 consecutive patients with severe hemophilia A (factor VIII activity, <0.01 IU per milliliter) who were born between 2000 and 2010 and collected data on all clotting-factor administration for up to 75 exposure days.